Enzyme replacement for lysosomal diseases.
Following the demonstration of the nature of the enzymatic defects in the sphingolipid storage disorders in the mid-1960s, consideration was directed to the development of therapy for patients with these conditions. High on the list of possibilities was enzyme supplementation or replacement. Many years of arduous investigation and the development of novel protein targeting strategies were required to bring this concept to fruition. Enzyme replacement therapy (ERT) was eventually shown to be extraordinarily effective for patients with Gaucher disease, the most prevalent metabolic storage disorder of humans. Demonstration of the benefit of ERT in this disorder led to the extension of this approach to the treatment of other lysosomal storage disorders. This review presents the current status and anticipated developments in this field.
Brady
Roscoe O
RO
Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1260, USA. bradyr@ninds.nih.gov
D000795:Fabry Disease / Q000188:drug therapy*; D005776:Gaucher Disease / Q000188:drug therapy*; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy*; D006026:Glycoside Hydrolases / Q000627:therapeutic use*; D006801:Humans; D009083:Mucopolysaccharidoses / Q000188:drug therapy*
D006026:Glycoside Hydrolases